Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233.

Gurley SN, Abidi AH, Allison P, Guan P, Duntsch C, Robertson JH, Kosanke SD, Keir ST, Bigner DD, Elberger AJ, Moore BM 2nd.
Journal   J Neurooncol.
Species  
Analytes Measured   Akt , BAD , Caspase-3 , p53 , p70S6K , PARP , STAT3
Matrix Tested   Cell lysates
Year   2012
Volume  
Page Numbers  
Application   Phosphoproteins
Abstract
Glioblastoma multiforme (GBM) is the most common and devastating form of primary central nervous system malignancy. The prognosis for patients diagnosed with GBM is poor, having a median survival rate of 12-15 months. Despite modern advances in the development of antineoplastic agents, the efficacy of newer anti-cancer agents in the treatment of GBM is yet to be determined. Thus, there remains a significant unmet need for new therapeutic strategies against GBM. A promising chemotherapeutic intervention has emerged from studies of cannabinoid receptor agonists wherein tetrahydrocannabinol has been the most extensively studied. The novel cannabinoid ligand KM-233 was developed as a lead platform for future optimization of biopharmaceutical properties of classical based cannabinoid ligands. Treatment of U87MG human GBM cells with KM-233 caused a time dependent change in the phosphorylation profiles of MEK, ERK1/2, Akt, BAD, STAT3, and p70S6K. Almost complete mitochondrial depolarization was observed 6 h post-treatment followed by a rapid increase in cleaved caspase 3 and significant cytoskeletal contractions. Treatment with KM-233 also resulted in a redistribution of the Golgi-endoplasmic reticulum structures. Dose escalation studies in the orthotopic model using U87MG cells revealed an 80 % reduction in tumor size after 12 mg/kg daily dosing for 20 days. The evaluation of KM-233 against primary tumor tissue in the side flank model revealed a significant decrease in the rate of tumor growth. These findings indicate that structural refinement of KM-233 to improve its biopharmaceutical properties may lead to a novel and efficacious treatment for GBM.

View Publications

Related Products

Akt Signaling Whole Cell Lysate Kit
Akt, GSK-3β, p70S6K | Human, Mouse, Rat
Multiplex
ERK-STAT3 Cascade Whole Cell Lysate Kit
ERK-1/2, MEK 1/2, STAT3 | Human, Mouse, Rat
Multiplex
Phospho/Total BAD Whole Cell Lysate Kit
BAD | Human, Non-human primate
Multiplex
Apoptosis Whole Cell Lysate Kit
Caspase-3, p53, PARP | Human
Multiplex
Phospho-STAT Panel Kit
STAT3, STAT4, STAT5a/b | Human, Mouse, Rat
Singleplex
Phospho-STAT3 (Tyr705) Kit
STAT3 | Human
Singleplex
Total STAT3 Kit
STAT3 | Human
Singleplex
Phospho-Akt (Ser473) Antibody
Akt
Total Akt Antibody Bulk Product
Akt
Phospho-Akt (Ser473) Kit
Akt | Human, Mouse, Rat, Non-human primate
Singleplex
Total Akt Kit
Akt | Human, Mouse, Rat, Non-human primate
Singleplex
Akt Control Pack 1
Akt
Akt Signaling Panel II Whole Cell Lysate Kit
Akt, GSK-3β, p70S6K, S6RP | Human, Mouse, Rat
Multiplex
Ubiquitinated, Total p53 Whole Cell Lysate Kit
p53 | Human, Mouse, Rat
Multiplex
Total p53 Whole Cell Lysate Kit
p53 | Human, Mouse, Rat
Singleplex
Caspase-3 (cleaved) Whole Cell Lysate Kit
Caspase-3 | Human
Singleplex
Cleaved/Total Caspase-3 Whole Cell Lysate Kit
Caspase-3 | Human
Multiplex
Phospho(Ser473)/Total Akt Whole Cell Lysate Kit
Akt | Human, Mouse, Rat
Multiplex
Phospho-p70S6K (Thr389) Whole Cell Lysate Kit
p70S6K | Human, Mouse, Rat
Singleplex
Phospho-p70S6K (Thr421/Ser424) Whole Cell Lysate Kit
p70S6K | Human, Mouse
Singleplex
Total p70S6K Whole Cell Lysate Kit
p70S6K | Human, Mouse, Rat
Singleplex
Akt Signaling (Total Protein) Whole Cell Lysate Kit
Akt, GSK-3β, p70S6K | Human, Mouse, Rat
Multiplex
PARP (cleaved) Whole Cell Lysate Kit
PARP | Human
Singleplex
Phospho (Thr421/Ser424)/Total p70S6K Whole Cell Lysate Kit 5
p70S6K | Human, Mouse, Rat
Multiplex
Phospho-Akt (Thr308) Whole Cell Lysate Kit
Akt | Human, Mouse
Singleplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters